Inclusion Criteria:

          -  Histological confirmation of biopsy-proven non-Hodgkin lymphoma, excluding chronic
             lymphocytic leukemia, primary central nervous system (CNS) lymphoma and Burkitt's
             lymphoma; Note: small lymphocytic lymphoma (SLL) is allowed

          -  Patients with indolent non-Hodgkin lymphoma (NHL) must have had >= 1 regimen of
             rituximab-containing regimen; Note: this includes follicular lymphoma (FL), marginal
             lymphoma and mucosa-associated lymphoid tissue (MALT)

          -  Patient with aggressive NHL must have received prior therapy - at a minimum:

               -  Anti-CD20 monoclonal antibody unless tumor is CD20 negative and

               -  An anthracycline containing regimen

               -  Transformed FL must have had therapy for FL and be refractory to chemotherapy
                  for DLBCL

          -  Chemotherapy refractory disease in aggressive NHL is defined as

               -  Stable disease of =< 12 months or progressive disease as best response to most
                  recent chemotherapy containing regimen

               -  Disease progression or recurrence =< 12 months of prior autologous stem cell
                  transplantation (SCT)

          -  Patients with aggressive NHL must have failed autologous hematopoietic stem cell
             transplantation (HSCT), or are ineligible or not consenting to autologous HSCT

          -  Patient must have at least 3 measurable lesions that are >= 1.5 cm in one dimension;
             one of the lesions must be >= 2.0 cm and is amenable to image-guided cryoablation and
             multiple vaccine injections as determined by interventional radiology and principal
             investigator (PI) (including tumors that can be safely accessed using imaging
             guidance and treated with minimal risk to adjacent structures)

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, 2

          -  Absolute neutrophil count (ANC) >= 1000/mm3

          -  Absolute lymphocyte count >= 500/mm3

          -  Platelet count >= 75,000/mm3

          -  Hemoglobin >= 8.0 g/dL

          -  Total bilirubin =< 1.5 x upper limit of normal (ULN), unless due to Gilbert's disease

          -  Aspartate transaminase (AST/serum glutamic-oxaloacetic transaminase [SGOT]) and
             alanine transaminase (ALT/serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x ULN

          -  Creatinine =< 1.5 x ULN or calculated creatinine clearance >= 60 mL/min for subject
             with creatinine ˃ 1.5 x institutional ULN

          -  Negative serum pregnancy test for women of childbearing potential =< 7 days prior to
             registration; Note: a second pregnancy test may be required =< 72 hours prior to
             receiving the first dose of study medication

          -  Negative human immunodeficiency virus (HIV), hepatitis B and C, and tuberculosis (TB)
             test

          -  Provide written informed consent

          -  Willing to return to the enrolling institution for follow-up (during active treatment
             and active monitoring phase of the study)

          -  Ability to complete questionnaire(s) by themselves or with assistance

          -  Willing to provide tissue and blood samples for research purposes

          -  Willing to use adequate contraception while on the study and until 120 days after the
             last dose of study drug

        Exclusion Criteria:

          -  Any of the following:

               -  Pregnant women

               -  Nursing women

          -  Co-morbid systemic illnesses or other severe concurrent disease which, in the
             judgment of the investigator, would make the patient inappropriate for entry into
             this study or interfere significantly with the proper assessment of safety and
             toxicity of the prescribed regimens

          -  Serious non-malignant disease such as active infection, symptomatic congestive heart
             failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social
             situations or other conditions which in the opinion of the investigator would
             compromise protocol objectives

          -  Currently receiving or have received any other investigational agent considered as a
             treatment for the primary neoplasm =< 28 days or within 4 half-lives (whichever is
             shorter) of the agent prior to registration

          -  History of other primary malignancy requiring systemic treatment within 6 months of
             protocol enrollment; patients must not be receiving chemotherapy or immunotherapy for
             another cancer; patients must not have another active malignancy requiring active
             treatment with the following acceptable EXCEPTIONS:

               -  Basal cell carcinoma, squamous cell carcinoma, or melanoma of the skin that has
                  undergone or will undergo potentially curative therapy

               -  In situ cervical cancer that has undergone or will undergo potentially curative
                  therapy

          -  Prior allogeneic bone marrow or peripheral blood stem cell transplantation

          -  Prior autologous bone marrow or peripheral blood stem cell transplantation =< 100
             days prior to registration or if recovery from the transplant is inadequate

          -  Major surgery other than diagnostic surgery =< 4 weeks prior to registration

          -  Prior chemotherapy or radiation therapy =< 2 weeks prior to registration or who has
             not recovered (i.e. to =< grade 1 or baseline) from an adverse event due to the
             previously administered therapy

          -  History of hypersensitivity and anaphylactoid reactions to pneumococcal vaccine or
             any component of the formulation, including diphtheria toxoid

          -  Active autoimmune disease such as Crohn's disease, rheumatoid arthritis, Sjogrens'
             disease, systemic lupus erythematosis, or similar conditions requiring systemic
             treatment within the past 3 months or a documented history of clinically severe
             autoimmune disease/syndrome difficult to control in the past

               -  EXCEPTIONS:

                    -  Vitiligo or resolved childhood asthma/atopy

                    -  Intermittent use of bronchodilators or local steroid injections

                    -  Hypothyroidism stable on hormone replacement,

                    -  Diabetes stable with current management

                    -  History of positive Coombs test but no evidence of hemolysis

                    -  Psoriasis not requiring systemic treatment

                    -  Conditions not expected to recur in the absence of an external trigger

          -  Coagulopathy, including the use of Coumadin or heparin anticoagulants that cannot be
             discontinued for the cryoablation procedure; NOTE: heparin for line patency without
             detectable lab abnormalities for coagulation will be allowed

          -  Corticosteroid use =< 2 weeks prior to registration; NOTE: patients must be off
             corticosteroids for at least 2 weeks prior to registration; this includes oral, IV,
             subcutaneous, or inhaled route of administration; patients on chronic corticosteroid
             for adrenal insufficiency or other reasons may enroll if they receive less than 10
             mg/day of prednisone (or equivalent)

          -  Active CNS malignancy

          -  Evidence of interstitial lung disease or active, non-infectious pneumonitis

          -  Received a live vaccine =< 30 days prior to registration

          -  New York Heart Association classification III or IV cardiovascular disease or recent
             myocardial infarction or unstable angina pectoris or cardiac arrhythmia =< 30 days
             prior to registration